"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 6 | 6 | 12 |
| 2002 | 28 | 9 | 37 |
| 2003 | 48 | 12 | 60 |
| 2004 | 39 | 16 | 55 |
| 2005 | 30 | 14 | 44 |
| 2006 | 41 | 17 | 58 |
| 2007 | 56 | 37 | 93 |
| 2008 | 53 | 29 | 82 |
| 2009 | 66 | 23 | 89 |
| 2010 | 66 | 28 | 94 |
| 2011 | 55 | 36 | 91 |
| 2012 | 46 | 40 | 86 |
| 2013 | 48 | 42 | 90 |
| 2014 | 40 | 25 | 65 |
| 2015 | 41 | 38 | 79 |
| 2016 | 43 | 34 | 77 |
| 2017 | 43 | 41 | 84 |
| 2018 | 46 | 38 | 84 |
| 2019 | 35 | 38 | 73 |
| 2020 | 23 | 32 | 55 |
| 2021 | 30 | 22 | 52 |
| 2022 | 5 | 37 | 42 |
| 2023 | 3 | 13 | 16 |
| 2024 | 15 | 11 | 26 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 Sep 10; 8(17):4487-4501.
-
Momelotinib for the treatment of myelofibrosis. Blood. 2024 Aug 15; 144(7):708-713.
-
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). Eur J Cancer. 2024 Sep; 209:114241.
-
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother. 2024 Jul; 25(10):1391-1404.
-
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11(9):e682-e692.
-
Efficacy and safety of NTRK inhibitors in patients with NTRK fusion-positive lung and thyroid cancers. Clin Adv Hematol Oncol. 2024 Jul-Aug; 22 Suppl 5(6):1-20.
-
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15; 391(7):585-597.
-
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial. Haematologica. 2024 06 01; 109(6):1977-1983.
-
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma. Neuro Oncol. 2024 May 03; 26(Supplement_2):S155-S164.
-
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma. PLoS One. 2024; 19(4):e0289902.